The PD-1102 trial in advanced Parkinson’s disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach
Objective: To present 3-year safety and clinical outcome data from a phase 1b, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor…IS THE HYPOXIA EXPOSURE BENEFICIAL FOR PEOPLE WITH PARKINSON’S DISEASE? A SCOPE REVIEW
Objective: To explore the current evidence and identify knowledge gaps, we conducted a scoping review about the hypoxia exposure effects on people with Parkinson’s disease…Long-term safety and activity of ecopipam (ECO), a selective D1 antagonist during treatment of pediatric patients with Tourette Syndrome
Objective: To evaluate the long-term safety and activity of ecopipam (ECO) in the treatment of children and adolescents with Tourette syndrome (TS). Background: D2 antagonists…Homeostatic Improvement of Brain Bioenergetic Metabolism in Parkinson’s Disease: Results From A Phase 2 REPAIR-PD Clinical Trial With CNM-Au8
Objective: To determine the effects of the nanocatalytic drug, CNM-Au8, on brain energy metabolites in Parkinson’s Disease. Background: Converging lines of evidence are identifying brain…Weeding Through the Haze: A Survey on Cannabis Use Among People with Parkinson’s Disease
Objective: To identify themes in cannabis use among people with Parkinson’s disease to inform medical recommendations and the design of future clinical trials. Background: Parkinson’s…Pridopidine for the Treatment of Early Huntington’s Disease
Objective: Assess the efficacy of pridopidine 45 mg bid for maintenance of total functional capacity (TFC) and motor function in early HD patients. Background: Pridopidine…Translatable biomarkers in gene therapy for Huntington’s Disease: learnings from pre-clinical studies
Objective: We have developed AAV5-miHTT, a recombinant AAV-based gene therapy expressing an engineered microRNA that specifically binds to HTT exon1, resulting in lowering of both…Effect of herbal medicine against Parkinson’s Diseases- An in silico studies
Objective: To evaluate the effect of the bioactive compounds of Gymnema sylvestre on treatment of Parkinson’s diseases. Background: Neurodegenerative diseases, such as Parkinson’s and Alzheimer’s,…Gut Microbiota in Parkinson’s disease: influences of device-assisted therapies
Objective: To determine the temporal stability of gut microbiota (GM) profiles around the acute establishment of advanced Parkinson's disease (PD) therapies and describe resulting alterations in…Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease
Objective: To assess the efficacy and safety of pridopidine in PD patients with Levodopa-induced dyskinesia (LID). Background: Pridopidine is a small molecule in clinical development…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 11
- Next Page »